12:34 PM EDT, 03/13/2024 (MT Newswires) -- NeuroBo Pharmaceuticals ( NRBO ) said Wednesday it received the go-ahead to continue its mid-stage clinical trial of DA-1241 without modification, a treatment for metabolic dysfunction-associated steatohepatitis, a liver disease.

A safety review committee approved the continuation following a blinded safety review of the first six months of study conduct, the company said.

DA-1241 is a two-part phase 2a trial. The company expects a full data readout from the trial in H2 2024.

NeuroBo stock was down 10% in recent trading.

Price: 4.38, Change: -0.49, Percent Change: -10.06